
    
      This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled,
      parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous
      vedolizumab (300 mg) infusion in induction and maintenance therapy in Japanese participants
      with moderately or severely active Crohn's disease.
    
  